In my opinion, this was a terrible, disappointing CC. I believe Leronlimab is an answer to COVID, HIV, some cancers, and a few other things but it appears that CYDY's team is not able to move things along in spite of the rosy forecasts and PR they have released in the last few months. It seems it is always on the verge of a major step forward but never there. Instead, each time they have only moved half way. Moving half way each time will never get to the goal. The whole mild/medium versus severe seems farcical. We have lots of statistically significant data that no one else has BUT the FDA doesn't seem to care. They want something else . . . severe trial data. So, why did we waste the time and the expense of doing the mild/medium trial when no one but CYDY cares? Consequently, that trial appears to have done nothing to move things along so that patients can get CYDY's molecule. Frustrating. Sorry I’m venting on this, but the CC did not really explain how the management could be so badly misreading the signals being given by the FDA and U.K. Obviously, this is all my opinion based on the little that I know from the CCs and PR statements, but that is my point.